Last updated: February 24, 2026
What is NDC 29300-0333?
NDC 29300-0333 refers to a specific drug product listed in the National Drug Code system. It is identified as Emgality (galcanezumab-gnlm) injection for the prevention of migraine in adults, manufactured by Eli Lilly and Company.
Market Landscape
Product Overview
- Indication: Prophylaxis of migraine in adults.
- Administration: Subcutaneous injection, typically once monthly.
- Approval Date: September 2018 (FDA).
- Formulation: 120 mg per pre-filled pen or syringe.
Competitors
| Drug Name |
Dosage Form |
Indication |
Market Launch Year |
Market Share (2022) |
| Aimovig (erenumab) |
Monthly injectable |
Prevention of migraine |
2018 |
40% |
| Ajovy (fozenezumab) |
Monthly or quarterly injection |
Migraine prevention |
2018 |
25% |
| Emgality (galcanezumab) |
Monthly injection |
Migraine prevention |
2018 |
20% |
| Vyepti (eptinezumab) |
Quarterly intravenous infusion |
Migraine prevention |
2020 |
15% |
Note: Data are estimates based on IQVIA IMS reports (2022).
Market Size
- The US market for migraine preventive biologics totaled approximately $2.2 billion in 2022.
- Emgality's sales contributed roughly $440 million.
- The global market is expanding, driven by increasing migraine prevalence and broader acceptance of biologics.
Key Drivers
- Rising migraine diagnoses, especially among women aged 35-55.
- Physician preference for targeted biologic therapies over traditional preventives.
- Growing insurance coverage, including Medicaid and private insurers.
- Expanded indications for migraine prophylaxis.
Barriers
- High treatment cost: Emgality's annual list price exceeds $6,000.
- Competitive market: Key players include Aimovig and Ajovy, with similar efficacy.
- Safety and tolerability profiles.
- Reimbursement challenges in some regions.
Price Projections
Historical Pricing
- 2018-2022: List prices ranged from $6,400 to $6,800 annually.
- Patient out-of-pocket: Variable, typically $30-$150 per injection, depending on insurance coverage.
Factors Influencing Future Prices
- Market competition: Introduction of biosimilars or new entrants could pressure prices.
- Regulatory decisions: Expanded indications or label updates might increase utilization.
- Reimbursement policies: Insurance coverage adjustments can impact net prices.
- Manufacturing costs: Advances in production might reduce costs over time.
Projected Price Trends (2023-2027)
| Year |
Typical List Price per Year |
Key Influences |
| 2023 |
~$6,500 |
Stable, market competition pressures persist |
| 2024 |
~$6,300 |
Slight pricing decline possible via competitive pressure |
| 2025 |
~$6,000 |
Potential for discounts with increased market share |
| 2026 |
~$5,800 |
Cost reductions via manufacturing efficiencies |
| 2027 |
~$5,600 |
Market saturation may drive further discounts |
These projections assume no significant policy changes or new competitors entering the market.
Revenue Outlook
- Emgality's revenue is projected to decline slightly as the market saturates, barring new indications or expanded access.
- Total sales may stabilize at approximately $400-$450 million annually through 2027.
- Price adjustments will influence revenue; a 10% reduction in price yields notable impact on top-line sales.
Strategic Considerations
- Market share growth: New prescribing guidelines or expanded labeling may boost utilization.
- Pricing strategy: Maintaining price competitiveness is critical amid evolving payer policies.
- Pipeline developments: Entry of alternative therapies or biosimilars could decrease pricing power.
- Geographic expansion: Growth in international markets presents new revenue avenues.
Key Takeaways
- NDC 29300-0333 (Emgality) is a key player in the migraine prevention biologic market, with approximately 20% market share in the US.
- The drug faces competition from Aimovig and Ajovy, with sales estimated at around $440 million in 2022.
- Pricing remains high but is expected to decline slowly over the next five years, influenced by competition, policy, and manufacturing efficiencies.
- Revenue stability depends on market expansion, payer coverage, and pipeline developments.
- Monitoring regulatory updates and new therapeutic entrants is vital for accurate forecasting.
FAQs
1. What factors could accelerate price declines for Emgality?
Introduction of biosimilars, increased market competition, regulatory pressure to reduce drug costs, and payer negotiations.
2. How does insurance coverage impact Emgality’s market penetration?
Better coverage and lower out-of-pocket costs increase prescribing rates and patient adherence.
3. Are there upcoming indications that could influence the market size?
Current label expansion to additional headache types or related neurological conditions could increase demand.
4. How does Emgality compare to oral migraine preventives?
Biologics like Emgality offer targeted, sustained efficacy but come at higher costs. Prescriber preference depends on patient response and tolerability.
5. What are the main risks to Emgality’s revenue growth?
Emergence of effective biosimilars, changes in reimbursement policies, or a shift in physician preference towards alternative therapies.
References
[1] IQVIA IMS. (2022). US Pharmaceuticals Market Data.
[2] FDA. (2018). FDA approval for galcanezumab for migraine prophylaxis.
[3] Eli Lilly. (2023). Emgality prescribing information.
[4] MarketWatch. (2023). Biologic migraine therapy market report.
[5] Medicare and private payer reimbursement policies.
